213 related articles for article (PubMed ID: 28159857)
1. Glycosylation is a global target for androgen control in prostate cancer cells.
Munkley J
Endocr Relat Cancer; 2017 Mar; 24(3):R49-R64. PubMed ID: 28159857
[TBL] [Abstract][Full Text] [Related]
2. Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability.
Munkley J; Vodak D; Livermore KE; James K; Wilson BT; Knight B; Mccullagh P; Mcgrath J; Crundwell M; Harries LW; Leung HY; Robson CN; Mills IG; Rajan P; Elliott DJ
EBioMedicine; 2016 Jun; 8():103-116. PubMed ID: 27428423
[TBL] [Abstract][Full Text] [Related]
3. The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer.
Munkley J; Oltean S; Vodák D; Wilson BT; Livermore KE; Zhou Y; Star E; Floros VI; Johannessen B; Knight B; McCullagh P; McGrath J; Crundwell M; Skotheim RI; Robson CN; Leung HY; Harries LW; Rajan P; Mills IG; Elliott DJ
Oncotarget; 2015 Oct; 6(33):34358-74. PubMed ID: 26452038
[TBL] [Abstract][Full Text] [Related]
4. The role of glycans in the development and progression of prostate cancer.
Munkley J; Mills IG; Elliott DJ
Nat Rev Urol; 2016 Jun; 13(6):324-33. PubMed ID: 27091662
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers.
Chen Z; Gulzar ZG; St Hill CA; Walcheck B; Brooks JD
Prostate; 2014 Jul; 74(10):1059-67. PubMed ID: 24854630
[TBL] [Abstract][Full Text] [Related]
6. The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer.
Hodgson K; Orozco-Moreno M; Scott E; Garnham R; Livermore K; Thomas H; Zhou Y; He J; Bermudez A; Garcia Marques FJ; Bastian K; Hysenaj G; Archer Goode E; Heer R; Pitteri S; Wang N; Elliott DJ; Munkley J
Sci Rep; 2023 Oct; 13(1):17031. PubMed ID: 37813880
[TBL] [Abstract][Full Text] [Related]
7. UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation.
Itkonen HM; Engedal N; Babaie E; Luhr M; Guldvik IJ; Minner S; Hohloch J; Tsourlakis MC; Schlomm T; Mills IG
Oncogene; 2015 Jul; 34(28):3744-50. PubMed ID: 25241896
[TBL] [Abstract][Full Text] [Related]
8. Pro-Survival Factor EDEM3 Confers Therapy Resistance in Prostate Cancer.
Scott E; Garnham R; Cheung K; Duxfield A; Elliott DJ; Munkley J
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897761
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
Scott E; Hodgson K; Calle B; Turner H; Cheung K; Bermudez A; Marques FJG; Pye H; Yo EC; Islam K; Oo HZ; McClurg UL; Wilson L; Thomas H; Frame FM; Orozco-Moreno M; Bastian K; Arredondo HM; Roustan C; Gray MA; Kelly L; Tolson A; Mellor E; Hysenaj G; Goode EA; Garnham R; Duxfield A; Heavey S; Stopka-Farooqui U; Haider A; Freeman A; Singh S; Johnston EW; Punwani S; Knight B; McCullagh P; McGrath J; Crundwell M; Harries L; Bogdan D; Westaby D; Fowler G; Flohr P; Yuan W; Sharp A; de Bono J; Maitland NJ; Wisnovsky S; Bertozzi CR; Heer R; Guerrero RH; Daugaard M; Leivo J; Whitaker H; Pitteri S; Wang N; Elliott DJ; Schumann B; Munkley J
Oncogene; 2023 Mar; 42(12):926-937. PubMed ID: 36725887
[TBL] [Abstract][Full Text] [Related]
10. Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation.
Shah P; Wang X; Yang W; Toghi Eshghi S; Sun S; Hoti N; Chen L; Yang S; Pasay J; Rubin A; Zhang H
Mol Cell Proteomics; 2015 Oct; 14(10):2753-63. PubMed ID: 26256267
[TBL] [Abstract][Full Text] [Related]
11. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
12. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
13. Canonical and Noncanonical Androgen Metabolism and Activity.
Storbeck KH; Mostaghel EA
Adv Exp Med Biol; 2019; 1210():239-277. PubMed ID: 31900912
[TBL] [Abstract][Full Text] [Related]
14. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects.
Fujimura T; Shinohara Y; Tissot B; Pang PC; Kurogochi M; Saito S; Arai Y; Sadilek M; Murayama K; Dell A; Nishimura S; Hakomori SI
Int J Cancer; 2008 Jan; 122(1):39-49. PubMed ID: 17803183
[TBL] [Abstract][Full Text] [Related]
15. Androgen control of lipid metabolism in prostate cancer: novel insights and future applications.
Butler LM; Centenera MM; Swinnen JV
Endocr Relat Cancer; 2016 May; 23(5):R219-27. PubMed ID: 27130044
[TBL] [Abstract][Full Text] [Related]
16. Glycosylation: Rising Potential for Prostate Cancer Evaluation.
Kałuża A; Szczykutowicz J; Ferens-Sieczkowska M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359624
[TBL] [Abstract][Full Text] [Related]
17.
Conroy LR; Stanback AE; Young LEA; Clarke HA; Austin GL; Liu J; Allison DB; Sun RC
Mol Cancer Res; 2021 Oct; 19(10):1727-1738. PubMed ID: 34131069
[TBL] [Abstract][Full Text] [Related]
18. Androgen signaling and its interactions with other signaling pathways in prostate cancer.
Kaarbø M; Klokk TI; Saatcioglu F
Bioessays; 2007 Dec; 29(12):1227-38. PubMed ID: 18008377
[TBL] [Abstract][Full Text] [Related]
19. Androgen receptor-related diseases: what do we know?
Shukla GC; Plaga AR; Shankar E; Gupta S
Andrology; 2016 May; 4(3):366-81. PubMed ID: 26991422
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor signaling in androgen-refractory prostate cancer.
Grossmann ME; Huang H; Tindall DJ
J Natl Cancer Inst; 2001 Nov; 93(22):1687-97. PubMed ID: 11717329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
